All articles tagged: Postpartum depression (F53.0)
Evalytics
25 March at 05.43 AM
A new $16,000 postpartum depression drug is here. How will insurers handle it?Zuranolone, a newly approved treatment for postpartum depression, offers promise for sufferers, but access remains uncertain due to lacking insurance coverage guidelines. While zuranolone presents a novel approach to treating depression by targeting hormone function, its high cost and insurance ambiguity pose barriers to widespread use. |
HealthDay
15 December at 08.35 PM
Drug Maker Says Women Can Now Access Postpartum Depression PillZurzuvae (zuranolone), the first postpartum depression pill approved for use in the United States, is now available to women who need it. The medication, which is now stocked in specialty pharmacies, can also be shipped directly to patients, Biogen and Sage Therapeutics Inc. said in a news release Thursday."Having an option like Zurzuvae that ca |
|
HealthDay
28 November at 10.58 PM
Neighborhood Disadvantage Tied to Higher Postpartum Depression RiskResiding in more disadvantaged neighborhoods is associated with a greater risk for postpartum depression (PPD), according to a study published online Nov. 13 in JAMA Network Open.Ticara L. Onyewuenyi, M.D., M.P.H., from Kaiser Permanente Northern California in Oakland, and colleagues examined whether neighborhood disadvantage is a |
|
HealthDay
08 November at 11.50 PM
New Postpartum Depression Drug Comes With Hefty Price TagA new drug to treat postpartum depression will cost nearly $16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients will not be able to afford the medication.Zurzuvae (zuranolone) was first <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depressi |
Medical xPress
30 June at 07.40 AM
Decision to offer sedation for often-painful IUD insertion is 'groundbreaking,' health experts sayIntrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during the insertion. But it wasn't until recently that providers began to acknowledge this and do something about it. |
|
HealthDay
27 June at 03.19 PM
Immunoglobulin Replacement Therapy Beneficial for Blood CancersImmunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum |
Medpage Today
26 June at 04.59 PM
When Was the Last Time You Really Talked With Your Patient?My 10 o'clock patient's name is Maria*. Her chart has three "health maintenance" flags that are bright red, indicating that she is more than 3 years overdue for a mammogram, more than 6 years overdue for a Pap smear, and has... |
|
Medpage Today
23 June at 09.21 PM
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2DORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks... |
|
Medpage Today
22 June at 06.00 PM
Fenofibrate Slows Diabetic Retinopathy ProgressionORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative... |
|
Medpage Today
22 June at 06.00 PM
Preventing Surgical-Site Infections; Drugs Go Head to Head for Ischemic StrokeTTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... |
|
|
Medical xPress
22 June at 05.20 PM
Lawsuit could challenge trust in Ozempic and other popular weight loss drugsThe manufacturers of the most popular weight loss drugs are being challenged in court. |
|
HealthDay
21 June at 03.38 PM
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is LowThe overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study published online June 10 in JAMA Internal Medicine.Priti Bandi, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the contemporary preval |
|
Medpage Today
13 June at 06.56 PM
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?Finding a way to dissociate the activity of effector T cells from regulatory T cells could make immune checkpoint inhibitors more effective in the 60% of melanoma patients who do not benefit or develop resistance to the drugs... |
|
Medpage Today
08 June at 04.00 PM
Here Are the Top Supreme Court Health Cases to WatchBy early July, the Supreme Court will release its most controversial rulings for the 2023-2024 term. The Court's 6-3 conservative supermajority has already overturned Roe v. Wade, sharply limited affirmative action, expanded... |
Newsletter for Healtcare
Join over 1.2M subscribers and receive one weekly email.
